生存时间不仅仅是生存：肿瘤临床试验的终点。
There Is More to Length of Survival Than Survival: Endpoints in Oncology Trials.
机构信息
Department of Medicine, Comprehensive Cancer Center, University of Chicago, Chicago, Illinois.
Department of Public Health Sciences, University of Chicago, Chicago, Illinois.
出版信息
Clin Cancer Res. 2024 Aug 1;30(15):3098-3099. doi: 10.1158/1078-0432.CCR-24-0772.
Progression-free survival as a primary endpoint for comparative trials does not fully capture the therapeutic risk/benefit ratio. Additionally, summarization of the treatment effect via a hazard ratio is problematic when the proportional hazards assumption is violated. Restricted mean survival time metrics may address these challenges but have other limitations. See related article by Chang et al., p. 3282.
无进展生存期作为比较试验的主要终点不能完全反映治疗的风险/获益比。此外，当违反比例风险假设时，通过危险比对治疗效果进行总结也是有问题的。受限平均生存时间指标可能解决这些挑战，但也有其他限制。有关 Chang 等人的相关文章，请参见第 3282 页。
Zotero 插件